OncoMatch/Clinical Trials/NCT06664411

Pola-ZR2P in Previously Untreated DLBCL

Is NCT06664411 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy for diffuse large b-cell lymphoma.

Phase 2RecruitingNavy General Hospital, BeijingNCT06664411Data as of May 2026

Treatment: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy — The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify